Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
55.5M
-
Shares change
-
+1.97M
-
Total reported value, excl. options
-
$911M
-
Value change
-
+$36.7M
-
Put/Call ratio
-
0.74
-
Number of buys
-
87
-
Number of sells
-
-65
-
Price
-
$16.40
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2017
203 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2017.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.5M shares
of 295M outstanding shares and own 18.84% of the company stock.
Largest 10 shareholders include BlackRock Inc. (6.87M shares), FMR LLC (5.36M shares), WASATCH ADVISORS INC (4.7M shares), Vanguard Group Inc (4.48M shares), STATE STREET CORP (3.98M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.4M shares), BAKER BROS. ADVISORS LP (2.11M shares), Casdin Capital, LLC (1.4M shares), Invesco Ltd. (1.38M shares), and D. E. Shaw & Co., Inc. (1.36M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.